Verastem, Inc. (VSTM) Stock Grade

About Verastem, Inc.'s fundamentals

Verastem is a biotechnology company with a market capitalization of $682.8 million that demonstrated exceptional revenue growth of 209.1% year-over-year, indicating significant commercial traction. However, the company is currently unprofitable, with a net margin of -677.6%, and reported a net loss in its latest annual statement, reflecting the capital-intensive nature of biotech development. The company does not pay a dividend. These metrics suggest Verastem is in a growth phase where revenue expansion is outpacing profitability, a common profile for emerging biotechnology firms investing heavily in product development and commercialization.